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The oncogenic transcription factor Activator Protein-1 (AP-1) is a DNA binding protein that 
assembles through dimerization of Fos and Jun protein subunits, their leucine-rich helical 
sequences entwining into a coiled coil structure. This study reports on downsizing the 
protooncogene cFos protein (380 residues) to shorter peptides (37-25 residues), modified 
with helix-inducing constraints to enhance binding to Jun. A crystal structure is reported for 
a 37-residue Fos-derived peptide (FosW) bound to Jun. This guided iterative downsizing of 
FosW to shorter peptide sequences, constrained into water-stable alpha helices by 
connecting amino acid sidechains to form cyclic pentapeptide components. Structural 
integrity in the presence and absence of Jun was assessed by circular dichroism 
spectroscopy, while thermodynamics of binding to cFos was measured by isothermal 
titration calorimetry. A 25-residue constrained peptide, one-third shorter yet 25% more 
helical than the structurally characterised 37-residue Fos-derived peptide, retained 80 % of 
the binding free energy due to pre-organisation in a Jun-binding helix conformation, with 
entropy gain (TΔS = + 3.2 kcal/mol) compensating for enthalpy loss. Attaching a cell 
penetrating peptide (TAT48-57) and a nuclear localisation signal (SV40) promoted cell uptake, 
localisation to the nucleus, and inhibition of the proliferation of two breast cancer cell lines. 
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INTRODUCTION 
Most biological functions are mediated by protein-protein interactions (PPIs), often 
involving large protein surface areas and shallow binding interfaces that are not conducive to 
targeting with conventional drug-like small molecules. An alternative approach under 
intensive investigation is to downsize one of the interacting protein surfaces, often a helix, to 
a bioactive small peptide capable of functionally mimicking or antagonizing the PPI 1. Short 
peptide sequences do not form thermodynamically stable helices in water. However, amino 
acid variations based on known α-helical propensities 2, together with incorporating helix 
constraints, can realise potent peptidic and peptidomimetic antagonists of PPIs 1,3, and some 
efficacious peptides have entered clinical trials 4. The helix constraints pre-organise peptides 
in receptor-binding α-helical conformations 5, with improved protein-binding affinities 6, 
protease resistance 7,8 and, in some cases, increased cellular uptake 6. Lactam bridges have 
been shown to be the most effective constraints for inducing peptide α-helicity 9. 
Appropriately placed constraints have been shown to induce helicity and compensate for loss 
of enthalpy and binding free energy normally associated with considerable truncation5. They 
have be used in conjunction with peptide truncation to derive small helical peptides that 
penetrate cell membranes 10. Helix constraints can therefore compensate for the loss of 
binding free energy, associated with shortening peptide sequences, by pre-organizing 
peptides to minimize the entropy penalty for rearranging to a protein-binding helical 
conformation 5. 
Activator Protein-1 (AP-1) is a dimeric transcription factor that is hyperactivated in 
tumourigenesis 11,12 and therefore antagonism of its function represents a promising 
therapeutic strategy for a number of human cancers 13. AP-1 consists of different sub-units 
that are assembled via a bZIP domain. This is composed of a DNA-binding basic region and a 
‘leucine zipper’ region involving a supercoiled heterodimer region of Jun (cJun, JunB, JunD) 
and Fos (cFos, FosB-1 and 2, Fra-1 and 2) proteins 14. The Jun-Fos coiled coil binding interface 
features pseudo-parallel alignments of α-helical segments of Jun and Fos that make contacts 
over the length of the helices 15. This PPI is difficult to target with hydrophobic drug-like 
molecules due to the lack of well-defined hydrophobic pockets 16 and to the difficulty in 
discriminating between the two interacting helical segments of Jun and Fos proteins. Small 
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molecules examined to date have lacked Jun/Fos specificity 17,18, which is essential given that 
some AP-1 compositions have been shown to be anti-oncogenic 12. 
AP-1 can be antagonised by cJun mutants that lack transactivation domains 19,20, by 
cJun and cFos mutants with truncated DNA-binding domains 21, and by mutations in DNA-
binding domains that then require an extended dimerisation interface 22. These mutant 
peptides bind efficiently to Jun and, when expressed in cells, can inhibit AP-1 to cause cell 
cycle arrest and reduced cell proliferation 22-24. However, such polypeptides are susceptible 
to degradation by proteases, do not permeate cell membranes, and have low bioavailability. 
Here we investigate the possibility of deriving short helical peptides from the Jun-binding 
region of cFos, a protein consisting of 380 amino acid residues featuring a leucine zipper 
region for heterodimerisation with Jun, a basic region for binding to DNA, and a 
transactivation domain at its C-terminus. We report steps towards minimising the length of 
the Fos fragment, altering it using helix constraints to optimise Fos-Jun interactions, and 
modifying the peptides further for entering cancer cells and targeting AP-1 in the nucleus to 
inhibit proliferation. This minimalist approach using helix constraints is still an under-utilised 
strategy for modulating protein-protein interactions, but it is unclear whether it can be useful 
in producing effective antagonists of protein-protein interactions specifically involving coiled 
coils that tend to involve key interactions along their entire interface 25. 
 
RESULTS 
Structure of FosW-Jun, a model protein-protein interface 
We have previously used an intracellular protein-fragment complementation method 
26 to derive a 37-residue peptide FosW 27 from a cFos-based library. This peptide was able to 
bind Jun and antagonise both Fos-Jun and Jun-Jun protein-protein interactions, but the 
structure of FosW-Jun is unknown. Here we have complexed FosW with Jun, obtained 
diffracting crystals, and determined a crystal structure to a resolution of 2.3 Å (Figure 1 and 
Table S1) (PDB ID: 5fv8). This is the first crystal structure of an AP-1 antagonist in complex 
with its target, and importantly identifies the anticipated binding mode of FosW with Jun 26. 
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Inspection of the crystal structure shows that FosW and Jun have bound together to 
form a parallel dimeric coiled coil, with characteristic hydrophobic interactions (ai-a’i and di-
d’i) and electrostatic contacts (gi-e’i+7 and ei-g’i-7) (Figure 1 and Supplementary Information). 
Consistent with other coiled coils 3, all ten residues at positions a and d are appropriately 
aligned for burying hydrophobic side chains away from the water solvent. This confers a major 
energy contribution to dimerisation 28, with interatomic distances consistent with important 
structure-stabilising interhelical a-a’ and d-d’ interactions 15,29. Thus our selection of 
predominantly bulky hydrophobic side chains to substitute at positions a of FosW has 
evidently improved sidechain packing in the core relative to cFos residues (TΔL, TΔI, KΔN and 
KΔL), thereby increasing enthalpy and driving dimerization. 
Interactions between g1 E and e’2 K, and g3 E and e’4 R are potentially helix-
stabilising. Residues at g2, e’3, e3, g’2, e4 and g’3 are correctly positioned to make similar 
interhelical interactions, but are too far apart to form contacts. Finally, an anticipated e2–g’1 
E–K interaction is not present in the crystal structure; rather the g’1 K amine nitrogen faces 
away from the e2 E. The crystal structure indicates that g2 R interacts with solvent rather than 
with g3 E. The e4 E does not interact with g’3 T, but may shield FosW a4 I from solvent with 
its hydrocarbon chain. Similarly, e1 and g4 Q residues, which have no g’i-7 or e’i+7 partner, 
shield a2 I and d4 L core residues. Finally, we note that positions b, c and f are occupied by 
residues that are not significantly involved in interhelical interactions according to the crystal 
structure, instead appearing to be involved in solvent interaction for solubility. Possible 
exceptions may be intrahelical interactions, such as a proposed salt bridge between f3 K and 
b4 E, with attraction of f4 K towards the b4 E and a cation–π attraction between b3 Y and f3 
K. The contributions of these intrahelical interactions to α-helix adoption and dimerisation 
free energies are, however, expected to be small. As such, FosW b, c and f positions may 
tolerate replacement residues that form helix constraints without significantly affecting the 
PPI interface 26. 
 Jun is predicted to be a more attractive target than Fos because of a more typical and 
hydrophobic interface at a and d positions of the Jun heptads (Figure 1) compared to the polar 
T/K-containing Fos core 26,27. As a consequence, Fos is reported to be unable to form 
homodimers, and requires Jun family members to form transcriptionally active heterodimers 
30. Complexes containing Jun are also more potent for transcriptional transactivation 30, and 
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Jun has been implicated in a number of cancers 11,12, making antagonists of this particular 
homologue potentially valuable. Therefore, we have concentrated here on downsizing Fos 
rather than Jun to create antagonists of the Fos-Jun protein-protein interaction.  
 
Downsizing FosW via helix-inducing constraints  
The major aim was to introduce one or more helix-inducing constraints into the FosW 
sequence to enable downsizing of the molecule while maintaining helicity and ultimately 
affinity for cJun. All helix-constrained peptides lacked five residues that served as N-terminal 
and C-terminal capping motifs within the FosW parent peptide. This led us to iteratively 
examine the effect on helix induction and affinity using one or more such constraints placed 
at different positions within the sequence, while concomitantly truncating the sequence from 
either terminus (see Figure 2 and Supplementary Information). 
An (iài+4) lactam bridge was first incorporated at different positions along the 
sequence to learn which heptad regions was most amenable to modification with a helix-
inducing constraint. This was achieved by cross-linking two amino acid residues at positions 
shown to have minimal involvement in Fos-Jun interhelical interactions in the crystal 
structure, namely b-to-f or f-to-c in the heptad repeat units of FosW (Figure 2, compounds 1-
5 and Figure S1).  Compounds 1 and 3 had similar helicity (44% and 40%) to FosW (41%), while 
compounds 2, 4 and 5 were more alpha-helical (62%, 59%, 79% respectively). However, only 
compounds 1 and 2 showed higher binding affinity for Jun (Kd 9.6 nM, 16.2 nM) relative to 
FosW (Kd 39 nM), whereas 4 and 5 had binding comparable to FosW (Kd 40 nM and 29 nM). 
Compound 3 did not display any affinity for Jun indicating that crosslinking at those positions 
was unproductive. 
 Since 1 had the highest binding affinity, a lactam bridge crosslinking residues K29-D33 
was retained in compounds 6-9 (Figure 2), which also contained a second bridge between 
residues 4-8, 8-12, 15-19 or 23-26 to further increase helicity (53%, 85%, 78% and 82%) over 
the moderately helical compound 1 (44%). Compounds 7, 8, and 9 retained affinity for Jun (Kd 
8.6 nM, 9.9 nM and 11 nM) while 6 had slightly less affinity. Since 7-9 retained affinity (Kd <10 
nM) and had high helicity (>70 %), the constraints used in these compounds became the focus 
of our efforts to downsize FosW. 
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Neither 22-residue peptides 10 and 11, with lactam bridges at positions 15-19, 22-26 
and 29-33, nor the same length peptides 12 and 13 with lactam crosslinks from positions 8-
12, 15-19 and 22-26 (12-13), were able to bind to Jun (trance did not exceed the non-
interaction average or displayed low Tm values), and only 10 had helicity above 40%. 
Extending the N-terminus to 25 residues, while incorporating a lactam crosslink at positions 
22-26 gave 14-15, with Kd 2.2 μM and 1 μM respectively. Removing the 22-26 bridge resulted 
in loss of binding affinity. Compound 15 was highly alpha helical (65%). Shortening the peptide 
to 22 residues (17) abolished affinity for Jun. 
In an effort to restore binding affinity, the sequence length was extended to 29 
residues. Compounds were truncated from the N-terminus and lactam bridges inserted at 
positions 7-11 and 29-33 (18), or 11-15 and 29-33 (19). These compounds had significant 
binding affinity (Kd = 56 nM and 100 nM) and helicity (72% and 64%). Subsequent truncation 
from the N-terminus of 19 to 25 residues gave compound 20 with higher affinity (Kd 2 μM) 
and alpha helicity (85 %) (Figure S1). 
Having identified some shorter peptides, isothermal titration calorimetry (ITC) (Figure 
3 and Figure S2) was used to assess enthalpic and entropic energy contributions to binding to 
Jun (Table 1). Compounds 14 and 15 had the highest negative entropy of binding (TΔS = -5.7 
and -5.2 kcal per mol), while peptides 18-20 had improved ΔG retention. The 25mer peptide 
20 retained substantial binding free energy through entropic gain and was a good 
compromise between shortening the sequence (reducing enthalpy) and constraining the helix 
(increasing entropy). 
Helicity is expected to be an important contributor to binding affinity 2,5. Interacting 
peptides had homomeric helicities ≥ 39 % with a mean helicity (63 %) substantially higher 
than for FosW (41 %), whilst non-interacting peptides had a mean helicity of 37 %, close to 
that of FosW. When mixed with Jun, interacting peptides had heteromeric helicities ≥44 % 
with a mean helicity (55 %), much higher than FosW–Jun (37 %), whilst non-interacting 
peptides had a mean helicity of 26 %. However, contrary to expectations, there were no 
strong relationships between helicity, affinity and entropy beyond these qualitative 
thresholds (See Supplementary Information). 
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Peptide 20 binds Jun effectively via entropic pre-organisation  
Peptide 20 consists of a NΔ9CΔ3 peptide (loss of 9 residues from the N-terminus and 
3 from the C-terminus relative to FosW; Figure 2) and can make 8 a/d and 2 e/g favourable 
interactions with Jun, compared with 10 a/d and 3 e/g favourable interactions for FosW 
binding to Jun. It also produced coiled coils with Jun that were much more helical (62 %) than 
FosW–Jun (37 %) (Figure 3). The increased helicity can be attributed to the two helix 
constraints positioned at the N- and C-terminus. Therefore despite truncation of one-third of 
the sequence relative to FosW, 77 % of the binding energy was maintained. Furthermore, 20 
displayed the expected entropy benefit conferred by the two helix constraints, a significant 
gain of +3.2 ± 0.5 kcal/mol to TΔS compared to FosW–Jun (Figure 3), thereby compensating 
for a loss of enthalpy accompanying the sequence shortening from FosW. Peptide 20 
demonstrated that the N-terminus of FosW is not absolutely required for Jun interaction, and 
that N-terminal truncation is possible with correct placement of helix-inducing constraints. 
The success of peptide 20 is striking when comparing the helicity of 20–Jun (62 %) with the 
unconstrained counterpart, LIN20–Jun (38 %). The latter is comparable to that of FosW–Jun 
(37 %) but, in contrast, displayed insignificant heterodimerisation compared to either dimer 
as measured by thermal denaturation experiments (Figure 3). As a result, the binding of 20 to 
Jun (Kd 2.0 ± 0.0 μM) is almost 30-fold greater than for LIN20 (Kd ≈ 55 μM) (Figure 3). 
 
Development of cell permeable compounds 
Compounds 18 (29 residues) and 20 (25 residues) were identified as compromises 
between truncating the peptide sequence and retaining some of the affinity observed for 
FosW (37 residues) binding to Jun. To investigate whether these peptides would enter cells, 
fluorescein isothiocyanate (FITC) was coupled to their N-terminus via a flexible linker (6-
aminohexanoic acid) to allow detection via flow cytometry and live cell confocal microscopy. 
There was negligible uptake of either FITC-18 or FITC-20 into MCF-7 breast cancer cells after 
1 h or 6 h (Figure 4B).  Thus, further modification of these peptides to promote cell uptake or 
penetration was needed if these compounds were to exhibit biological activity in cells. Three 
strategies were investigated for delivering these helix-constrained peptides into cells: 
attaching a lipid, appending a cell penetrating peptide (CPP) sequence, or replacing the polar 
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helix-constraining lactam bridges with more hydrophobic helix-constraining hydrocarbon 
linkers.  
Firstly, palmitic acid was conjugated to the N-terminus of peptide 20 to give Pal-20, 
anticipated to interact with the lipid bilayer to enhance uptake 31. However, the conjugate 
showed no significant binding to Jun, as measured by CD or ITC techniques. Secondly, the first 
ten residues of cationic cell penetrating peptide sequence TAT derived from HIV-1 32 was 
attached to the C-terminus of 20 to give 20-TAT48-57, but this is only known to enhance peptide 
uptake into the cytoplasm, not the nucleus. An additional nuclear localisation signal sequence 
from the SV40 large T-cell antigen 33 was therefore also appended to produce 20-NLS-TAT48-
57, for the purpose of both enhancing cell uptake and directing 20 to the nucleus. These 
peptide appendages did not significantly affect binding affinity for Jun, and a positive TΔS 
term was maintained (Table 1). The third strategy involved replacing the lactam bridges in 
compounds 18 and 20 with more hydrophobic hydrocarbon bridges to give 18-HC and 20-HC, 
which was found to reduce binding affinity for Jun (Kd 320 nM and 15 µM, respectively) but 
maintain a positive TΔS term (Table 1). 
Cell uptake was monitored by flow cytometry using FITC labelled analogues of 18HC, 
20HC, 20-TAT48-57 and 20-NLS-TAT48-57 (Figure 4B). 20-NLS-TAT48-57 showed the highest cell 
uptake with the most fluorescence at 1h and 6 h, comparable to FITC-labelled TAT48-57 alone.  
20-TAT48-57 showed a large increase in fluorescence at 6h, whilst 18HC and 20HC had 
comparable levels of cell uptake after 6 h. We next analysed these peptides by live cell 
confocal microscopy to observe how these compounds were distributed throughout the cell. 
FITC-18HC and FITC-20HC localised differently within MCF-7 cells. FITC-18HC was freely 
distributed throughout the cytosol and the nucleus, whereas FITC-20HC was mainly trapped 
within endosomes or aggregated within the cell (Figure 4B). TAT48-57 (FITC-20-TAT48-57) showed 
cytosolic uptake and a small amount of nuclear localisation. However, addition of the nuclear 
localisation signal (FITC-20-NLS-TAT48-57) promoted very efficient cellular uptake and led to 
much greater nuclear localisation. All four compounds were distributed differently in the cells, 
potentially impacting on their biological properties. 
 
Antiproliferative activity in human breast cancer cells 
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Both MCF-7 and ZR75-1 are breast cancer cell lines that are dependent on AP-1 activity 
for proliferation 34,35. Having demonstrated that C-terminal appendage of cationic cell 
penetrating peptides was sufficient to facilitate efficient cellular uptake and nuclear 
localisation of 20, or alternatively that hydrocarbon staples were sufficient to facilitate cell 
uptake and nuclear localisation of 18, we next sought to investigate whether these peptides 
inhibited cell proliferation. Treatment with 20, 20HC, 18 or 18HC did not affect proliferation 
of MCF-7 or ZR75-1 cells at the concentrations tested (Figure 4C, 4D). However, 20-TAT48-57 
did significantly reduce proliferation of both MCF-7 (83 % reduction) and ZR75-1 cells (70 % 
reduction) at 30 μM, while 20-NLS-TAT48-57 at the same concentration reduced proliferation 
to an even greater extent (95 % and 96 % respectively, Figure 4D). Neither TAT48-57 nor NLS-
TAT48-57 alone at the same concentration reduced cell viability (Figure 4C, 4D), and no peptide 
showed any haemolytic activity on red blood cells after six hours at peptide concentrations 
up to 30 μM, indicating that cell viability was not inhibited by the peptides through non-
specific membrane disruption (Table S2).  
These results indicate that our successful strategy of downsizing Fos to helix-
constrained short peptides has overcome the energy barrier to binding Jun, but the next 
hurdle is to modify the short peptide antagonists for cell uptake and nuclear localisation. Cell 
uptake was achieved by making the helix constraints more hydrophobic, but a nuclear 
localisation signal was still required to access the intracellular target of Fos peptides and affect 
proliferation of AP-1 containing breast cancer cells. These important steps taken here to 
target the Fos-Jun binding interface provide a valuable platform for further development of 
Fos-derived small molecules as AP-1 inhibitors in cancer therapy.  
 
DISCUSSION 
Helix constraints confer affinity to cFos peptides enabling their shortening  
 The 37-residue truncated analogue of cFos (FosW) has been crystallised here in 
complex with a Jun peptide. FosW is an antagonist of the interaction of Jun with Fos 26. The 
crystal structure of FosW-Jun has identified the relative positioning of amino acid sidechains 
in FosW and Jun and their specific involvement in inter-helix interactions that stabilise the 
heterodimer in a coiled-coil complex (Figure 1). The structure provides valuable information 
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as to the optimal sites for modifying Fos without disrupting interhelical interactions. 
Nevertheless, truncating this peptide was found to substantially attenuate binding affinity for 
Jun, due principally to loss of binding enthalpy, as demonstrated by the linear counterpart of 
20 (LIN20) (Table 1). To compensate for this loss of enthalpy upon truncating the FosW 
sequence, we have investigated the effect of incorporating one, two or three helix-inducing 
(i→i+4) lactam bridges at positions in FosW away from the helix-helix binding interface with 
Jun. These constraints were anticipated to reduce the conformational entropic penalty for 
helix formation 36. Promotion of helicity was anticipated to improve binding affinity for Jun, 
which is dependent on a supercoiling event between helical partners 2,37,38. By increasing 
helicity in truncated FosW analogues, we anticipated reducing the entropic penalty 
associated with pre-organising the shortened helix for target binding, a strategy used 
successfully to enable downsizing of other α-helical partners in protein-protein interactions 
5,6,39. 
Lactam helix-inducing constraints at (i→i+4) positions were chosen due to their ability 
to impart greater alpha helicity per residue relative to other linkers, such as hydrocarbons, 
triazoles, m-xylene thioether and alkyl thioether 9, and due to the simplicity and minimal 
sequence disturbance of merely connecting amino acid sidechains to form lactams. 
Positioning these cyclic pentapeptide motifs within the FosW sequence induced substantial 
α-helicity (60-77 %) relative to the linear sequence, despite significant shortening. However, 
we find here that high helicity alone in Fos peptide analogues does not guarantee high affinity 
for Jun (See Supplementary Information), reinforcing the importance of sequence in coiled 
coil formation and stability. The use of helix constraints was anticipated to permit at least 
some truncation of the FosW sequence without loss of Jun binding. Indeed, truncation from 
either terminus coupled with careful positioning of the helix-inducing constraints between 
non-interfacial b, c and f residues, particularly at peptide termini, has successfully enabled 
identification of truncated peptides which maintain both high helicity and affinity for Jun 
(Figure 2, 3). 
Compounds 18 (29 residues, Kd 56 nM) and 20 (25 residues, Kd 2 µM) were identified 
as compromises between shortening the peptide sequence (22 % and 33 %, respectively) 
relative to FosW and retaining some of the affinity observed for FosW (37 residues) binding 
to Jun. Additionally, 18 and 20 retained high helicity (69 % and 62 %, respectively) when bound 
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to Jun (15% helical in isolation27), compared with 72% and 85% in isolation (i.e. homodimeric). 
For 20 there was a clear entropic gain that contributed to the favourable interaction free 
energy, and this partially compensated for a loss in binding enthalpy. Conversely, LIN20 
suffered the same enthalpic loss as 20 (within 1.1 kcal/mol), but without constraints there 
was no entropy gain, and so ΔG was reduced by 43 % compared to FosW. The helix-inducing 
constraints in 20 therefore provide 19% of the free energy of binding compared to the 
unconstrained peptide, translating to a 27-fold improvement in affinity for Jun. This finding 
demonstrates the value of helix-inducing constraints in truncated peptides for maintaining 
significant bioactivity. Peptides 20 and 18 were therefore chosen for the next stage, the 
testing of cellular uptake and functional activity. These two peptides show greater ligand 
efficiency (ΔG per unit molecular weight), higher entropy gain, and greater water solubility 
than similar length analogues, 14 and 15.  
 
Helicity, entropic stabilisation and binding affinity 
Helix-inducing constraints are expected to confer an entropy advantage by pre-
organising peptides in the helix-binding conformation preferred by the target. Molecules with 
greater helicity might better form coiled-coils 5,37,38, however we find this to be an over-
simplification. For the case of a coiled coil, there is likely a limit to the entropy value of pre-
organising a helical structure. Above a certain threshold helicity, conformational entropy may 
oppose coiled-coil formation 27, perhaps reflecting a need for flexibility in a helix to enable 
some distortion necessary for supercoiling 40,41. A key issue with a coiled-coil is that there is 
usually a fairly even contribution of residues along the entire coil to the binding energy, with 
fewer hot spots localised in a single region of the sequence that can form the basis for 
truncation. It is notable that truncation to 20 results in substantial loss of enthalpy, consistent 
with enthalpy contributions from residues all along the coiled coil 5. This may prevent further 
antagonist truncation, requiring innovation to increase both entropy and enthalpy through 
unnatural amino acid replacements that still enable coiled coil formation. Consequently, very 
few short helical antagonists of coiled coil PPIs have been described in the literature to date 
25. 
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Cell uptake and nuclear localisation 
AP-1 is localised in the cell nucleus, so the development of Fos-derived peptides that 
can antagonise Fos-Jun binding is only the first step towards drugs that can modulate AP-1 in 
vivo. The unconstrained and polar FosW peptide antagonist of Jun–Fos binding has low 
conformational stability, high susceptibility to degradation by proteases in blood and in cells, 
and poor permeability across cell membranes. Helix constraints have been found to improve 
all of these properties for some peptides 5,6. However, cellular uptake is difficult to predict. It 
is highly dependent on the peptide sequence, the type of helix constraint, and the cell type 
42.  
Given the size of our short FosW-derived peptides compared to cellular Jun and Fos 
proteins, it was our aim to assess their ability to compete with these for an interaction with 
Jun inside the cell. We chose 20 for assessment of cellular uptake and nuclear localisation 
because of its higher affinity (Kd 2 μM) compared to the shortest Jun-derived antagonist of 
Jun-Fos interactions (Kd 7.3 μM) reported previously 5, and the greater expected value of Fos-
peptides as antagonists against oncogenic Jun 11,12,30 than for Jun-peptides against cFos 5. 
While lactam-bridges were very effective as helix-inducing constraints in FosW-derivative 
peptides, there was no evidence for cell internalisation of 20. Previous reports of the cell 
penetrating potential of hydrocarbon constrained peptides 42 encouraged the synthesis of the 
analogue FITC-20HC. While that peptide did pentrate cells, it did not display favourable 
intracellular distribution for AP-1 targeting. The longer peptide analogue 18HC, which also 
had higher affinity for Jun than 20HC, was also generated to compare cellular uptake and 
activity. Cell uptake did increase, but there was little uptake into the nucleus and 
consequently the peptide concentration may not have been high enough for AP-1 inhibition. 
We therefore added TAT48-57 or a NLS-TAT48-57 appendage to help drive higher cell uptake and 
target more 20 to the cell nucleus where AP-1 is active (Figure 4). TAT48-57 increased uptake 
and favourable distribution, which further increased with additional inclusion of the NLS 
sequence (Figure 4). Considering the minimal concentrations (µM) known to be required for 
internalisation of cationic CPP conjugates 43, these conjugates of 20 were considered to have 
been delivered at a minimum effective concentration. Cytoplasmic co-translational/post-
translational sequestration of Jun before nuclear transport may also be desirable to expedite 
Jun degradation by cytoplasmic ubiquitin/proteasomal pathways. Thus, the improved nuclear 
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and cytosolic presence of 20-NLS-TAT48-57 over 20-TAT48-57 was considered to be promising for 
AP-1 inhibition. 
 
Antiproliferative activity of 18 and 20 in breast cancer cells  
AP-1 is known to be overexpressed in many breast cancers 44, where it drives tumour 
initiation and development 45, and thus is an important target for cancer therapy. MCF-7 and 
ZR75-1 breast cancer cells are dependent on AP-1 for expression of a variety of genes in 
response to pro-oncogenic growth factors 34, including extracellular matrix metalloproteinase 
MMP9 46,47 and G1→S phase regulator Cyclin D1 24,35, such that reduced metastatic potential 
and cancer cell proliferation results from repression of these genes. Poor uptake, endosomal 
trapping and/or aggregation, and low Jun binding affinity may have prevented 20HC from 
affecting cell viability, whilst poorly internalised 18HC also did not reduce cancer cell viability 
despite apparently avoiding endosomal trapping or aggregation (Figure4B). However, 
conjugation of both TAT48-57 and the SV40 NLS to 20 led to significant reduction in the viability 
of both MCF-7 and ZR75-1 breast cancer cells. This suggests that cell and nuclear penetration 
were the limiting factors for AP-1 inhibition by 20 since TAT48-57 and NLS appendages alone had 
no effect on cell viability and non-specific cell lysis was negligible. Thus, we have 
demonstrated that once sufficiently internalised into the cell nucleus, 20 displays significant 
inhibition of AP-1-driven oncogenesis. Moreover, once internalised the CPP component of the 
peptide is predicted to expendable, without significant effect on the activity of 20.  
 
CONCLUSION 
The strategy of iterative sequence truncation, coupled with insertion of helix-inducing 
constraints at appropriate positions, was used to reduce the size of Fos to peptide fragments 
as antagonists of Fos-Jun coiled coil formation. The first crystal structure of an AP-1 
antagonist, a Fos-derived peptide complexed with Jun, was used to design helix-constrained 
and truncated peptides that similarly bound to Jun. Several rounds of iteration led to peptides 
18 and 20, which were efficient Jun-binding ligands relative to their size and were able to 
inhibit the Fos–Jun interaction. Compounds 18 and 20 represented compromises between 
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downsizing to a minimal binding sequence and retaining appreciable binding affinity for Jun. 
Isothermal titration calorimetry measurements revealed that the helix-inducing constraint 
provided an entropic advantage for binding to Jun relative to analogous unstructured short 
peptides. Importantly, the cell penetrating peptide TAT48-57 together with the nuclear 
localisation signal peptide SV40, or alternatively a hydrocarbon (i→i+4) helix-constraining 
linker, enabled substantial cell uptake and delivery of 18 and 20 into the nucleus of cells where 
AP-1 is active. With these adaptations, compound 20 was able to both enter the nucleus of 
cancer cells and reduce their proliferation in vitro at low µM concentrations. This potency 
compares favourably with small molecule AP-1 inhibitors such as momordin I (IC50 ≈ 30 μM) 
and T-5524 (IC50 ≈ 10 μM) that have reached clinical trials 18,48. Compound 20 represents one 
of few examples to date of a helix-constrained peptide that can modulate a PPI featuring 
coiled-coil peptides 25,42. The approach highlighted here, using helix-inducing constraints to 
compensate for shortening the sequence of a binding partner in a coiled coil transcription 
factor, shows considerable promise. Further development of Jun antagonists based on 
truncating Fos is required to generate useful AP-1 inhibitors suitable for treating cancers 
featuring AP-1 dysregulation. 
 
METHODS    
Circular Dichroism (CD spectra and thermal melts) 
Coiled coil stability was analysed as previously described 5 using a Chirascan (Applied 
Photophysics) instrument, recording ellipticity of homotypic (peptide) or heterotypic (1:1 
peptide:Jun stoichiometric mix) samples at a total peptide concentration (Pt) of 150 μM, 
dissolved in 10 mM potassium phosphate buffer with 100 mM potassium fluoride, pH 7.  
Isothermal titration calorimetry (ITC) 
Coiled coil interaction thermodynamics were assessed as previously described 5 using a 
Microcal VP-ITC instrument (GE Healthcare). Jun at 100 μM - 3 mM was injected into peptide 
homotypic samples at 9 μM – 200 μM in circular dichroism buffer.  
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Further details of CD spectroscopy and ITC can be found in the Supplementary 
Information, along with full procedures for X-ray crystallography, cell culture and assays, and 
peptide haemolytic activity assay. 
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FIGURE LEGENDS 
Figure 1: Crystal structure of the FosW–Jun coiled coil. Top left: FosW and Jun sequences. 
Stabilising interhelical hydrophobic interactions (ai-a’i and di-d’i) are shown as vertical lines 
and specificity-conferring interhelical electrostatic interactions (gi-e’i+7 and ei-g’i-7), are shown 
as green arrows. Heptad register in italics above FosW sequence. Left: Helical wheel diagram 
of FosW (showing residues selected from Fos library in red) in interaction with Jun, including 
interhelical interactions between e and g residues (green arrows). Adapted from source 26. 
Right: Crystal structure of the FosW–Jun coiled coil at 2.3 Å resolution. Jun is shown as a green 
ribbon, FosW as a red ribbon. Side chains for a, d, e and g residues only are shown, using CPK 
colouring. Ribbons go from N-terminus (top) to C-terminus (bottom). See Table S1 for 
crystallisation and structure solving parameters. Model rendered with the PyMOL Molecular 
Graphics System, Version 1.8 Schrödinger, LLC. 
Figure 2: Helix-constrained and truncated Fos peptides. Design template FosW sequence in 
bold. Heptad register a-g through each heptad of FosW in italics. Helix constraints between 
lysine and aspartate are shown in blue. Standard single letter amino acid code except Pal = 
palmitic acid, TAT48-57 = First 10 residues of the HIV-1 Tat peptide 32, NLS = the monopartite 
SV40 large T-antigen nuclear localisation signal 33, Ac- = N-terminal acetyl modification, -NH2 
= C-terminal amine, X = (S)α-(2’-pentenyl)alanine. Dissociation constants (Kd) measured by 
isothermal titration calorimetry (ITC), and fractional helicites calculated from ellipticity 
measured by circular dichroism spectroscopy (CD) using Equation 4 (see Supporting 
Information) 49. Constraint of all heptads except Heptad 3 generated full length peptides 
(minus AS and GAP capping motifs) with similar dissociation constants to that of FosW but 
improved helicity, whist addition of a second constraint was generally effective in inducing 
further increased helicity, and even lower dissociation constants. Truncations from N- and C-
termini were effective if combined with optimal positioning of constraints. ITC experiments 
not performed because binding measured by CD was negligible are labelled “ND” (“not 
determined”). ITC experiments that generated binding too weak for accurate fitting are 
labelled “NF” (“not fit”). 
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Figure 3: Peptide 20 binds Jun and tolerates cell penetrating peptide appendages. Thermal 
denaturation profiles (A) and isothermal titration calorimetry (B) of peptide:Jun mixtures 
compared to FosW–Jun. (A) Thermal melt data is reported as change in mean residue 
ellipticity (MRE; units deg cm2/dmol), as a function of circular dichroism ellipticity at 222 nm 
with temperature. Blue: peptide alone, red: equimolar mix of peptide with Jun, grey: average 
of Jun and peptide alone (representing non-interaction), black: Jun alone. (B) Raw isotherms 
(top panels) and fitted data (bottom panels) (both baseline corrected) for peptides with Jun 
compared to FosW. Injection enthalpies for the buffer into buffer control (blue text label) on 
the NLS-TAT48-57 plot are translated by -0.05 μcal/sec for clarity relative to those for Jun into 
NLS-TAT48-57. In shortened peptide 20, constraints induce high helicity despite truncation, and 
this peptide retains significant binding free energy of FosW despite loss of interaction 
contacts due to entropic stabilisation. In contrast, linear counterpart LIN20 displays poor 
helicity and 27-fold reduced affinity for Jun compared to 20. 
Figure 4: Intracellular delivery of 18 and 20 alone versus with appended cationic cell 
penetrating peptides. (A) Peptides were incubated at 10 μM for one or six hours at 37 °C in 
serum free media on MCF-7 cells. Quantitation by flow cytometry with fluorescence intensity 
calculated from live single cells. Data shown are means (+ SEM) of four independent repeats 
(B) Live cell confocal microscopy of MCF-7 cells. Peptides were incubated at 10 μM for 6 h at 
37 °C in serum free media. Nuclei were counterstained with Hoechst. Scale bar = 20 μm. 
Viability of MCF-7 (C) and ZR75-1 (D) breast cancer cells after a 96-hour incubation with the 
indicated peptide concentrations in complete medium. Data is normalised to vehicle (DMSO) 
control. Data shown are means (+ SEM) of three independent experiments. * P < 0.05, **** 
P <0.0001 (Student's T-test) decrease relative to DMSO control. 
Table 1: Thermodynamic parameters for Jun interaction with lactam constrained FosW 
derivative peptides. Data from CD and ITC measurements (2 s.f.). θ is raw CD ellipticity 
(mdeg). Equations for fractional helicity and the Gibbs-Helmholtz equation, from which TΔS 
is calculated as ΔH – ΔG, are provided in the Supplementary Information. FosW–Jun CD values 
from Worrall and Mason (2011). CD values are taken from representative single 
measurements, which are typically reproducible in biological replicates to ± 1 °C for Tm, within 
5 % for fractional helicity and 222:208 ratio (θ222/208), and within 10 % for Kd and ∆G (data not 
shown). ITC values are the arithmetic mean of at least two independent titrations ± SDs, 
 22 
except values from Worrall and Mason (2011) indicated with an asterisk and values for 20-
TAT48-57 and 20-NLS-TAT48-57 (single titrations and fitting errors). CD and ITC data generally 
agree to within 15 % for ΔG and an order of magnitude for Kd. ITC experiments not performed 
because binding measured by CD was negligible are labelled “ND” (“not determined”). CD or 
ITC experiments that generated binding too weak for accurate fitting are labelled “NF” (“not 
fit”).  
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